EA201300585A1 - Иммуномодулирующие олигонуклеотиды - Google Patents

Иммуномодулирующие олигонуклеотиды

Info

Publication number
EA201300585A1
EA201300585A1 EA201300585A EA201300585A EA201300585A1 EA 201300585 A1 EA201300585 A1 EA 201300585A1 EA 201300585 A EA201300585 A EA 201300585A EA 201300585 A EA201300585 A EA 201300585A EA 201300585 A1 EA201300585 A1 EA 201300585A1
Authority
EA
Eurasian Patent Office
Prior art keywords
immunomodulatory oligonucleotides
compositions
immunomodulatory
oligonucleotides
disclosed
Prior art date
Application number
EA201300585A
Other languages
English (en)
Other versions
EA030096B1 (ru
Inventor
Грэйсон Б. Липфорд
Кристофер Фрейзер
Original Assignee
Селекта Байосайенсиз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Селекта Байосайенсиз, Инк. filed Critical Селекта Байосайенсиз, Инк.
Publication of EA201300585A1 publication Critical patent/EA201300585A1/ru
Publication of EA030096B1 publication Critical patent/EA030096B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Раскрыты композиции, которые содержат иммуностимулирующие нуклеиновые кислоты, вместе с применением таких композиций для индукции иммунных ответов.
EA201300585A 2010-11-16 2011-11-16 Способы, композиции и нуклеиновые кислоты для стимуляции гуморального иммунного ответа EA030096B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41419410P 2010-11-16 2010-11-16
PCT/US2011/061056 WO2012068295A1 (en) 2010-11-16 2011-11-16 Immunostimulatory oligonucleotides

Publications (2)

Publication Number Publication Date
EA201300585A1 true EA201300585A1 (ru) 2013-11-29
EA030096B1 EA030096B1 (ru) 2018-06-29

Family

ID=46084406

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201300585A EA030096B1 (ru) 2010-11-16 2011-11-16 Способы, композиции и нуклеиновые кислоты для стимуляции гуморального иммунного ответа

Country Status (14)

Country Link
US (1) US8546550B2 (ru)
EP (1) EP2640426B1 (ru)
JP (3) JP5933577B2 (ru)
KR (1) KR20130116890A (ru)
CN (2) CN103347542B (ru)
AU (2) AU2011329850B2 (ru)
BR (1) BR112013012195A2 (ru)
CA (1) CA2817746A1 (ru)
DK (1) DK2640426T3 (ru)
EA (1) EA030096B1 (ru)
ES (1) ES2569857T3 (ru)
IL (2) IL226299A (ru)
MX (1) MX344972B (ru)
WO (1) WO2012068295A1 (ru)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030129251A1 (en) * 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CN104531671A (zh) 2010-10-01 2015-04-22 现代治疗公司 设计核酸及其使用方法
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3492109B1 (en) 2011-10-03 2020-03-04 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
WO2013090648A1 (en) 2011-12-16 2013-06-20 modeRNA Therapeutics Modified nucleoside, nucleotide, and nucleic acid compositions
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US8999380B2 (en) 2012-04-02 2015-04-07 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
CN110743008A (zh) 2013-03-14 2020-02-04 哈佛大学的校长及成员们 基于纳米颗粒的组合物
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
BR112016007255A2 (pt) 2013-10-03 2017-09-12 Moderna Therapeutics Inc polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
CN105936906B (zh) * 2013-11-08 2019-06-21 上海交通大学 被修饰的含CpG序列单元的寡聚脱氧核苷酸分子及其用途
JP6881813B2 (ja) 2014-04-23 2021-06-02 モデルナティーエックス， インコーポレイテッド 核酸ワクチン
EP3169693B1 (en) 2014-07-16 2022-03-09 ModernaTX, Inc. Chimeric polynucleotides
WO2017077066A1 (en) * 2015-11-06 2017-05-11 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Composition comprising a biocompatible and biodegradable polymer, nanocarries and a drug and methods of making and using the same
CN108014333B (zh) * 2017-10-11 2020-10-20 江苏省农业科学院 动物用粘膜靶向免疫增强剂及其在兽用疫苗中的应用
WO2019164872A2 (en) * 2018-02-20 2019-08-29 University Of Florida Research Foundation, Inc. Composition and method for targeting natural killer cells in immunotherapy to overcome tumor suppression with manganese dioxide nanoparticles
MA52011A (fr) * 2018-03-16 2021-01-20 Zoetis Services Llc Vaccins peptidiques contre l'interleukine-31
US20210261964A1 (en) * 2018-07-19 2021-08-26 The Research Foundation For Microbial Diseases Of Osaka University LIPID PARTICLE CONTAINING A-TYPE CpG OLIGODEOXYNUCLEOTIDE
US20220226465A1 (en) 2021-01-18 2022-07-21 ConserV Bioscience Coronavirus Immunogenic Compositions, Methods and Uses Thereof
CN114796476A (zh) * 2021-09-24 2022-07-29 中国医学科学院医学生物学研究所 一种亚单位疫苗新型核酸佐剂系统及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030129251A1 (en) * 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US20020028784A1 (en) * 2000-03-10 2002-03-07 Nest Gary Van Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
PT1446162E (pt) * 2001-08-17 2009-01-27 Coley Pharm Gmbh Agrupamentos imunoestimuladores oligonucléotidos com actividade melhorada
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
KR101178816B1 (ko) * 2002-12-23 2012-09-07 다이나박스 테크놀로지 코퍼레이션 면역자극성 서열 올리고뉴클레오타이드 및 이의 이용방법
CN1296378C (zh) * 2004-05-17 2007-01-24 中国人民解放军第三军医大学 高免疫活性 CpG－S ODN 和拮抗 CpG－S ODN 作用的 CpG－N ODN 的基因序列及其应用
EP1796650B1 (en) * 2004-09-14 2009-01-07 NanoDel Technologies GmbH Delivery vehicle containing nanoparticles
JP2008531018A (ja) * 2005-02-24 2008-08-14 コーリー ファーマシューティカル グループ，インコーポレイテッド 免疫刺激性オリゴヌクレオチド
CN101460620B (zh) * 2006-05-31 2012-02-15 东丽株式会社 免疫刺激寡核苷酸及其药物用途
WO2008128123A1 (en) * 2007-04-13 2008-10-23 University Of North Texas Health Science Center At Fort Worth Formulation of active agent loaded activated plga nanoparticles for targeted cancer nano-therapeutics
EP2630966B1 (en) * 2007-10-12 2017-04-19 Massachusetts Institute of Technology Vaccine nanotechnology
US8343497B2 (en) * 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
EA201101530A1 (ru) * 2009-04-21 2012-03-30 Селекта Байосайенсиз, Инк. ИММУНОНАНОТЕРАПИЯ, ОБЕСПЕЧИВАЮЩАЯ Th1-СМЕЩЕННЫЙ ОТВЕТ
KR20120059572A (ko) * 2009-08-26 2012-06-08 셀렉타 바이오사이언시즈, 인크. Ｔ－세포 도움을 유도하는 조성물

Also Published As

Publication number Publication date
CN105327363A (zh) 2016-02-17
AU2011329850B2 (en) 2017-03-02
JP2014501504A (ja) 2014-01-23
CN103347542B (zh) 2015-09-16
MX344972B (es) 2017-01-12
IL226299A (en) 2017-05-29
US20120213812A1 (en) 2012-08-23
AU2011329850A1 (en) 2013-06-06
EP2640426A4 (en) 2014-11-05
IL226299A0 (en) 2013-07-31
AU2017203714A1 (en) 2017-06-22
EA030096B1 (ru) 2018-06-29
CA2817746A1 (en) 2012-05-24
JP5933577B2 (ja) 2016-06-15
ES2569857T3 (es) 2016-05-12
WO2012068295A1 (en) 2012-05-24
DK2640426T3 (en) 2016-05-02
US8546550B2 (en) 2013-10-01
JP6203897B2 (ja) 2017-09-27
KR20130116890A (ko) 2013-10-24
IL252061A0 (en) 2017-07-31
EP2640426A1 (en) 2013-09-25
BR112013012195A2 (pt) 2018-07-10
MX2013005544A (es) 2013-09-26
JP2016189777A (ja) 2016-11-10
EP2640426B1 (en) 2016-02-03
CN103347542A (zh) 2013-10-09
JP2018023389A (ja) 2018-02-15

Similar Documents

Publication Publication Date Title
EA201300585A1 (ru) Иммуномодулирующие олигонуклеотиды
CY1125029T1 (el) Τροποποιημενοι νουκλεοζιτες, νουκλεοτιδια, και νουκλεϊκα οξεα και χρησεις αυτων
MX2017008819A (es) Anticuerpos anti-cd47 y usos de los mismos.
WO2016019134A8 (en) Flagellin-based agents and uses including effective vaccination
EA201291157A1 (ru) Мультивалентные вакцины с синтетическими наноносителями
MX2017007731A (es) Composiciones de detergente, variantes de lipasa y polinucleotidos que codifican las mismas.
IL247469B (en) Methods for refining conjugates based on alpha il-15/il-15r, preparations containing products produced in this way and their uses
MX2020001159A (es) Composiciones y metodos que comprenden una variante de enzima lipolitica.
PH12015502216A1 (en) Compositions and methods for improving the health of aquatic animals
LT2986726T (lt) Naujos bacillus kamienų kompozicijos
PH12015501059A1 (en) Anti-hemagglutinin antibodies and methods of use
GB2537077A (en) Methods for sequencing nucleic acids
JO3755B1 (ar) تركيبات تستوستيرون
BR112013014204A2 (pt) composições de sucops espumantes
CY1120759T1 (el) Παρασκευη διγλυκοζιτη (s,s)-σεκοϊσολαρικιρεσινολης και διγλυκοζιτη (r,r)-σεκοϊσολαρικιρεσινολης
TR201905787T4 (tr) Liyofilize TAT-NR2B9C formülasyonu.
UY34702A (es) Composiciones y métodos agrícolas u hortícolas
HK1219426A1 (zh) 包含免疫刺激性寡核苷酸的新穎疫苗組合物
EP4227685A3 (en) Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus
UY34613A (es) Composición de limpieza
BR112013032223A2 (pt) molécula de ácido nucleico isolada, e, composição
EP3054945A4 (en) 3,3'-disubstituted indolines as inhibitors of cholesterol ester transfer protein
IN2014DN07270A (ru)
IT1403154B1 (it) Procedimento per la preparazione di tramezzini di tipo sushi.
FR2988729B1 (fr) Compositions de 2,4,4,4-tetrafluorobut-1-ene et de 1-methoxyheptafluoropropane

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU